The FDA has approved Hympavzi to prevent bleeding episodes in hemophilia A and B patients aged 12 and older. This innovative ...
The FDA has approved Pfizer’s marstacimab (Hympavzi ... under FDA review is Sanofi’s fitusiran. This siRNA-based drug knocks down levels of the anticoagulant antithrombin, potentially ...
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...
As October draws to a close, it's time to take a look at the regulatory news that made headlines in the month and look ahead to ...
This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive ...
Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ...
J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2024 and raised its full-year 2024 guidance(1) ...
Pfizer has beaten analyst estimate both top- and bottom line. The firm has also raised its full-year guidance. Read my ...
Shares of Sangamo Therapeutics surged 69% after the genetic medicines developer announced regulatory progress in its quest to ...